OARSI Theatre Presentation Showcases iPPS Biomarker Data
Latest announcements
Announcement summary
OARSI Theatre Presentation Showcases iPPS Biomarker Data
Paradigm’s Chief Medical Officer, Dr Donna Skerrett, delivered an oral presentation at the 2026 OARSI Congress in the US, highlighting Phase 2 (PARA_OA_008) biomarker data for iPPS in knee osteoarthritis. The data, also published in Arthritis Research & Therapy, demonstrated reductions in markers of cartilage degradation, inflammation and pain, with correlations to clinical outcomes. These findings provide further mechanistic support for Paradigm’s ongoing Phase 3 program.
Ask a question
Your question will be sent privately to Paradigm Biopharmaceuticals. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Paradigm Biopharmaceuticals a question about this announcement.